Who
Ronald Richard
Director
Company insider
Files Form 4 as: Director, Emergent BioSolutions.
In numbers
- Trades disclosed
- 112
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $10.0M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 20 Nov 2006
- Last trade
- 30 Apr 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 5 Dec 2025filed 9 Dec 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,748 at $0.00 | filing |
| 5 Dec 2025filed 9 Dec 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $86K7,100 at $12.11 | filing |
| 5 Dec 2025filed 9 Dec 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code M | $129K25,748 at $5.02 | filing |
| 5 Dec 2025filed 9 Dec 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $129K10,864 at $11.90 | filing |
| 5 Dec 2025filed 9 Dec 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $177K14,884 at $11.90 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,748 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —17,430 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —33,847 at $0.00 | filing |
| 25 Nov 2022filed 29 Nov 2022 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $23K1,912 at $11.94 | filing |
| 26 May 2022filed 31 May 2022 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —8,446 at $0.00 | filing |
| 20 May 2021filed 24 May 2021 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —5,027 at $0.00 | filing |
| 7 Aug 2020filed 11 Aug 2020 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $825K6,297 at $131.00 | filing |
| 3 Jun 2020filed 5 Jun 2020 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $575K6,572 at $87.51 | filing |
| 21 May 2020filed 26 May 2020 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —2,821 at $0.00 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Critical Survey: Emergent Biosolutions (NYSE:EBS) & Viridian Therapeutics (NASDAQ:VRDN)EBS · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Ronald Richard; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.